EphA2 Proteolytic Fragment as a Sensitive Diagnostic Biomarker for Very Early-stage Pancreatic Ductal Carcinoma.

Shinya Sato Masatoshi Nakagawa Takeshi Terashima Soichiro Morinaga Yohei Miyagi Eisaku Yoshida Toru Yoshimura Motoharu Seiki Shuichi Kaneko Makoto Ueno Taro Yamashita Naohiko Koshikawa

Published in: Cancer research communications (2023)

EphA2 N-terminus deletion is involved in pancreatic ductal carcinoma development from high-risk IPMN and EphA2-NF produced by cleavage can be used as a serum biomarker to diagnose pancreatic ductal carcinoma and predict pancreatic ductal carcinoma development from high-risk IPMN.

Keyphrases

early stage
signaling pathway
squamous cell carcinoma
oxidative stress
radiation therapy
immune response
inflammatory response
nuclear factor
toll like receptor
neoadjuvant chemotherapy
rectal cancer